Jump Into an All-New Mickey & Friends Adventure with Disney Illusion Island on July 28
9.2.2023 17:00:00 EET | Business Wire | Press release
Embark on a brand-new adventure with Disney Mickey Mouse’s triumphant return to video games – and this time he’s bringing a few friends! Today, Disney, in collaboration with developer Dlala Studios, revealed that Disney Illusion Island , an upcoming local cooperative 2D platform adventure video game for up to four players, will debut exclusively for Nintendo Switch™ on July 28, 2023. Additionally, pre-orders for Disney Illusion Island are available for $39.99 in Nintendo eShop and at retail, beginning today.
“Fans are in for a treat with the upcoming launch of the whimsical cartoon-like experience offered by Disney Illusion Island,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re thrilled to work with developer Dlala Studios as they expand upon the Mickey & Friends world with a new and original storyline, engaging gameplay and delightful hand-drawn art style.”
Join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy and set off on a perilous quest to explore the colorfully hand-crafted and yet mysterious island of Monoth in an escapade to recover three magical Tomes – powerful books used to protect the island. Featuring the voice actors of Mickey, Minnie, Donald, and Goofy and an original orchestral score, players can immerse themselves in a solo adventure or team up with up to three friends in local co-op to use special team skills such as Rope Drop, Leap Frog, and a heart gifting Hug to save the island. Discover rich biomes and never-before-seen environments, meet strange yet intriguing characters, and uncover hidden secrets galore!
But the journey will not be easy, and with intrigue afoot, not everything is what it seems on “Illusion Island.”
“Words cannot express how excited we are for players to embrace the Dlala-spin on this brand-new experience for Mickey Mouse, Minnie Mouse, Donald Duck and Goofy,” said AJ Grand-Scrutton, Lead Developer, Dlala Studios. “It has been an incredible honor working on this title and we hope that Nintendo Switch players and Disney fans worldwide love playing it as much as we've loved creating it.”
Disney Illusion Island will be available for $39.99 and will debut worldwide exclusively for Nintendo Switch on July 28, 2023.
For more information about Disney Illusion Island: https://games.disney.com/disney-illusion-island
To watch the latest trailer: https://www.youtube.com/watch?v=Ll9zSkf4Cfw
For Disney Illusion Island assets: https://drive.google.com/drive/folders/1sVurQkkRn_Tq94FDsbBipvWoP3-ssuhe?usp=sharing
For more updates on Disney Illusion Island, please follow us on social below:
About Dlala Studios
Dlala Studios are the creators of Battletoads (2020), and have previously worked on award-winning titles such as Sea of Thieves, The Escapists, and Lost Words: Beyond The Page. The Essex-based studio celebrated their 10th anniversary in 2022, and are currently developing Disney Illusion Island for the Nintendo Switch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005020/en/
Contact information
MEDIA CONTACT
Disney Consumer Products, Games and Publishing
Dashaun Gasque
Communications Manager
DASHAUN.GASQUE@DISNEY.COM
Dylan Quintero
Senior Specialist, Communications
DYLAN.QUINTERO@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom